Protein p53 - Structure, Function, and Possible Therapeutic Implications

Acta Dermatovenerologica Croatica

Volumn 11, Issue 4, 2003, Pages 225-230

  Batinac, Tanja ^a   Gruber, Franjo ^a   Lipozenčić, Jasna ^b   Zamolo Končar, Gordana ^c   Stašić, Adalbert ^a   Brajac, Ines ^a  

^a KBC RIJEKA   (Croatia)

^b UNIVERSITY OF ZAGREB   (Croatia)

^c UNIVERSITY OF RIJEKA   (Croatia)

Author keywords

Antineoplastic agents; Genes, p53; Neoplasms; Protein p53

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN P53;

APOPTOSIS; CELL CYCLE; CELL DIFFERENTIATION; CELL GROWTH; CELL PROLIFERATION; CLONE; DESQUAMATION; DNA BINDING; DNA DAMAGE; DRUG DESIGN; DRUG TARGETING; GENE INACTIVATION; GENE LOCATION; GENE MUTATION; GENE OVEREXPRESSION; GROWTH INHIBITION; HOMEOSTASIS; INHIBITION KINETICS; MOLECULAR BIOLOGY; PROTEIN ANALYSIS; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; PROTO ONCOGENE; REGULATORY MECHANISM; REVIEW; SKIN CARCINOGENESIS; SKIN STRUCTURE; TUMOR SUPPRESSOR GENE; VACCINE PRODUCTION;

GENES, P53; HUMANS; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0347087478     PISSN: 1330027X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Harris CC, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993;329:1318-27.
2. Furihata M, Sonobe H, Ohtsuki Y. The aberrant p53 protein. Int J Oncol 1995;6:1209-26.
3. Lane DP, Benchimol S. p53: oncogene or anti-oncogene. Genes Dev 1990;4:1-8.
4. Haake AR, Polakowska RR. Cell death by apoptosis in epidermal biology. J Invest Dermatol 1993;101:107-12.
5. Milner J. The role of p53 in the normal control of cell proliferation. Curr Opin Cell Biol 1991;3:282-6.
6. Deppert W, Buschhausen-Denker G, Patschinsky T, Steinmeyer K. Cell cycle control of p53 in normal (3T3) and chemically transformed (Meth A) mouse cells. II. Requirement for cell cycle progression. Oncogene 1990;5:1701-6.
7. Matsumura Y, Ananthaswamy HN. Short-term and long-term cellular and molecular events following UV irradiation of skin: implications for molecular medicine. Expert Rev Mol Med 2002;4:1-22.
8. Liang SB, Ohtsuki Y, Furihata M, Takeuchi T, Iwata J, Chen BK, et al. Sun-exposure- and aging-dependent p53 protein accumulation results in growth advantage for tumor cells in carcinogenesis of nonmelanocytic skin cancer. Virchows Arch 1999;434:193-9.
9. Hall PA, McKee PH, Menage H, Dover R, Lane DP. High levels of p53 protein in UV-irradiated normal skin. Oncogene 1993;8:203-7.
10. Jonason AS, Kunala S, Price GJ, Restifo RJ, Spinelli HM, Persing JA, et al. Frequent clones of p53-mutated keratinocytes in normal human skin. Proc Natl Acad Sci USA 1996;93:14025-9.
11. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 in the cellular response to DNA damage. Cancer Res 1991;51(23 Pt 1): 6304-11.
12. Nelson WG, Kastan M. DNA strand breaks: the DNA template alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol 1994;14:1815-23.
13. Hoffman B, Liebermann DA. Molecular controls of apoptosis: differentiation/growth arrest primary response genes, proto-oncogenes, and tumor suppressor genes as positive & negative modulators. Oncogene 1994;9:1807-12.
14. Hainaut P, Hollstein M. p53 and human cancer: the first ten thousand mutations. Adv Cancer Res 2000;77:81-137.
15. D'Errico MR, Dogliotti E. The role of p53 mutations in skin cancer. Chronica Dermatologica 1996;6:27-35.
16. Mowat MR. P53 in tumor progression: life, death, and everything. Adv Cancer Res 1998;74:25-48.
17. Levine AJ, Momand J, Finlay CA. The p53 tumor suppressor. Nature 1991;351:453-6.
18. Hall PA, Ray A, Lemoine NR. p53 immunostaining as a marker of malignant disease in diagnostic cytopathology. Lancet 1991;338:513.
19. Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev 1996;10:1054-72.
20. Helander SD, Peters MS, Pittelkow MR. Expression of p53 protein in benign and malignant epidermal pathological conditions. J Am Acad Dermatol 1993;29(5 Pt 1):741-8.
21. Soini Y, Kamel D, Paakko P, Lehto VP, Oikarinen A, Vahakangas KV. Aberrant accumulation of p53 associates with Ki67 and mitotic count in benign skin lesions. Br J Dermatol 1994;131:514-20.
22. Ro YS, Cooper PN, Lee JA, Quinn AG, Harrison D, Lane D, et al. p53 protein expression in benign and malignant skin tumors. Br J Dermatol 1993;128:237-41.
23. Helander SD, Peters MS, Pittelkow MR. p53 expression and localization in normal skin, psoriasis, cutaneous carcinoma and cultured keratinocytes. J Invest Dermatol 1992;98:636-41.
24. McNutt NS, Saenz-Santamaria C, Volkenandt M, Shea CR, Albino AP. Abnormalities of p53 protein expression in cutaneous disorders. Arch Dermatol 1994;130:225-32.
25. McGregor JM, Yu CC, Dublin EA, Levison DA, MacDonald DM. Aberrant expression of p53 tumor-suppressor protein in non-melanoma skin cancer. Br J Dermatol 1992;127:463-9.
26. Stephenson TJ, Royds J, Silcocks PB, Bleehen SS. Mutant p53 oncogene expression in keratoacanthoma and squamous cell carcinoma. Br J Dermatol 1992;127:566-70.
27. Tadini G, Cerri A, Crosti L, Cattoretti G, Berti E. p53 and oncogene expression in psoriasis. Acta Derm Venereol Suppl (Stockh) 1989;146:33-5.
28. Hannuksela-Svahn A, Paakko P, Autio P, Reunala T, Karvonen J, et al. Expression of p53 protein before and after PUVA treatment in psoriasis. Acta Derm Venereol 1999;79:195-9.
29. Bianchi L, Farrace MG, Nini G, Piacentini M. Abnormal Bcl-2 and "tissue" transglutaminase expression in psoriatic skin. J Invest Dermatol 1994;103:829-33.
30. Chung JH, Kwon OS, Eun HC, Youn JI, Song YW, Kim JG, et al. Apoptosis in the pathogenesis of cutaneous lupus erythematosus. Am J Dermatopathol 1998;20:233-41.
31. de Jong EM, van Erp PE, Ruiter DJ, van de Kerkhof PC. Immunohistochemical detection of proliferation and differentiation in discoid lupus erythematosus. J Am Acad Dermatol 1991;25(6 Pt 1):1032-8.
32. Saed GM, Ladin D, Olson J, Han X, Hou Z, Fivenson D. Analysis of p53 gene mutations in keloids using polymerase chain reaction-based single-strained conformational polymorphism and DNA sequencing. Arch Dermatol 1998;134:963-7.
33. Tuan TL, Nichter LS. The molecular basis of keloid and hypertrophic scar formation. Mol Med Today 1998;4:19-24.
34. Mercer WE, Shields MT, Lin D, Appella E, Ullrich SJ. Growth suppression induced by wild-type p53 protein is accompanied by selective down-regulation of proliferating-cell nuclear antigen expression. Proc Natl Acad Sci USA 1991;88:1958-62.
35. el-Deiry WS, Kern SE, Pientepol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nat Genet 1992;1:45-9.
36. Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 1994;265:346-55.
37. Lane DP, Crawford LV. T antigen is bound to a host protein in SV-transformed cells. Nature 1979;278:261-3.
38. Wrone-Smith T, Bergstrom J, Quevedo ME, Reddy V, Gutierrez-Steil C, Nickoloff BJ. Differential expression of cell survival and cell cycle regulatory proteins in cutaneous squamoproliferative lesions. J Dermatol Sci 1999;19:53-67.
39. Lane DP. Cancer. p53, guardian of the genome. Nature 1992;358:15-6.
40. Linke SP, Clarkin KC, Di Leonardo A, Tsou A, Wahl GM. A reversible, p53 dependent G0/G1 cell cycle arrest induced by ribonucleotide depletion in the absence of detectable DNA damage. Genes Dev 1996;10:934-47.
41. Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW. Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 1997;88:593-602.
42. Nigro JM, Aldape KD, Hess SM, Tlsty TD. Cellular adhesion regulates p53 protein levels in primary human keratinocytes. Cancer Res 1997;57:3635-9.
43. Banasiak KJ, Haddad GG. Hypoxia-induced apoptosis: effects of hypoxia severity and role of p53 in neuronal cell death. Brain Res 1998;797:295-304.
44. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, et al. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 1994;9:1799-805.
45. Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, et al. Gain of function mutations in p53. Nat Genet 1993;4:42-6.
46. Milner J, Medcalf EA. Cotranslation of activated mutant p53 wild type drives the wild-type p53 protein into the mutant conformation. Cell 1991;65:765-74.
47. Malkin D, Li FP, Strong LC, Fraumeni JF Jr, Nelson CE, Kim DH, et al. Germ line p53 mutations in a familiar syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990;250:1233-8.
48. Ueda H, Ullrich SJ, Gangemi JD, Kappel CA, Ngo L, Feitelson MA, et al. Functional inactivation but not structural mutation of p53 causes liver cancer. Nat Genet 1995;9:41-7.
49. Bold RJ, Termuhlen PM, McConkey DJ. Apoptosis, cancer and cancer therapy. Surg Oncol 1997;6:133-42.
50. Dummer R, Bergh J, Karlsson Y, Horowitz JA, Mulder NH, Huinink DT, et al. Biological activity and safety of adenoviral vector-expressed wild-type p53 after intramural injection in melanoma and breast cancer patients with p53-overexpressing tumors. Cancer Gene Ther 2000;7:1069-76.
51. Ben-Hur H, Ben-Meir A, Hagay Z, Ben-Meir A, Berman V, Schwartsburd B, et al. Tumor-preventive effects of the soluble p53 antigen on chemically-induced skin cancer in mice. Anticancer Res 1998;18:4237-41.